pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,802 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Opinion: Ebola outbreak response requires engaging with religious traditions and leaders
    “Failing to engage religious and traditional leaders in meaningful ways was a grave misstep in previous Ebola outbreaks,” researchers write.
    STAT · 1mo ago↗ source
  • STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
    Hospital execs agree that affordability is a major issue. What to do about it is less clear.
    STAT · 1mo ago↗ source
  • How a diabetes conference sparked a controversy
    Many in the diabetes research community expressed shock and disbelief that their colleagues were threatened with arrest for passing out paper copies of an editorial.
    STAT · 1mo ago↗ source
← prev
page 30 of 73
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
    STAT is tracking goals and promises of Robert F. Kennedy Jr. and his Make America Healthy Again movement — successes, incompletes, and fails.
    STAT · 1mo ago↗ source
  • STAT+: An obesity drug deep-dive, and peptides move mainstream
    Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow…
    STAT · 1mo ago↗ source
  • RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
    None of STAT's requests for Kennedy's schedule have been completed, and some haven't even been acknowledged.
    STAT · 1mo ago↗ source
  • Drinking during pregnancy rose after 2020, new CDC data suggest
    A new CDC report underscores that drinking during pregnancy, while generally thought of as a thing of the past, is still a matter of concern. 
    STAT · 1mo ago↗ source
  • STAT+: AMA and lawmakers push back on AI care denials
    In this edition of STAT Health Tech: HHS watchdog on denials by health insurers, lawmakers target AI denials, and Talkspace's new chatbot offering.
    STAT · 1mo ago↗ source
  • Nonprofit buys experimental cancer drug to maintain patient access
    In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug.
    STAT · 1mo ago↗ source
  • Study highlights influence of socioeconomic status on children’s brain development
    A new study found that the leading environmental factor influencing brain structure and function is the socioeconomic status of a child's family.
    STAT · 1mo ago↗ source
  • The seeming inevitability of rising healthcare costs
    We’re getting our first signs of where healthcare costs are heading next year. According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges
    Endpoints · 1mo ago↗ source
  • STAT+: Abridge inks deals with Nvidia and Lilly
    Abridge announced new deals with Eli Lilly and Nvidia as it aims to gain an edge in a competitive market.
    STAT · 1mo ago↗ source
  • Summit pulls $500M share sale a day after announcing it
    <figure><div><img src="https://imgproxy.divecdn.com/_dT9zKJsCoS0jrFraV8Vdkcut5aCVtKPN0y1PuLlKnE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTUwMzE2NTA1LmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says
    DHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendr…
    Endpoints · 1mo ago↗ source
  • Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
    <figure><div><img src="https://imgproxy.divecdn.com/Sl1QCaU_supqAvtEJA_tXhY8sXexPvdgos3TT-jjIM4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjA1MzM4Nzg3LmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • Summit withdraws $500M offering, citing 'market conditions'
    The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars. Summit Therapeutics ditched plans for a $500 milli…
    Endpoints · 1mo ago↗ source
  • STAT+: A suspicious denial pattern in Medicare Advantage
    Major Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.
    STAT · 1mo ago↗ source
  • Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
    Plus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic revie…
    Endpoints · 1mo ago↗ source
  • Camurus’ second CRL for acromegaly drug; Teva details workforce cuts
    Plus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer.…
    Endpoints · 1mo ago↗ source
  • Novartis RNA drug acquired in $12B Avidity deal notches a trial win
    <p>The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.</p>
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Novartis doubles down on molecular glue strategy
    Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Biopharma pay report: Top-paid CSOs, CMOs of 2025
    Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News…
    Endpoints · 1mo ago↗ source
  • Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
    Parabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...
    Endpoints · 1mo ago↗ source
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
    More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
    STAT · 1mo ago↗ source